Part 3: Factors Influencing Pharmaceutical Water Markets
By Mike Henley
Healthcare reform. During the past 15 months, this simple phrase has gained notoriety in many circles, depending on whether one supports or opposes the new law passed by the Congress and signed by the president in March. Regardless of oneﾒs viewpoint on what the politicians have done, this industry is an important water treatment market, and it is far too early to know whether or not the new law will stifle new product innovation (which could potentially impact treated water demand) as some opponents rightfully wonder, or if their fears are completely unwarranted. This article will examine the pharmaceutical water treatment marketplace. For the purposes of this article, this water treatment segment includes endusers who produce pharmaceutical-grade water because they are required to follow the guidelines set forth by the United States Pharmacopeial Convention Inc. (USP), or related pharmacopeia standards in other world regions (i.e., European Pharmacopeia [EP] or Japanese Pharmacopeia [JP]). Examples include pharmaceutical manufacturers, biopharmaceutical companies, some healthcare device makers, kidney dialysis centers, and the makers of certain consumer products (e.g., cosmetics, and contact lens solution, among others) that require pharmaceutical-grade water. Some background information is based on contacts with individuals who are involved with the suppliers who service endusers.
Log in or Subscribe to Access the Full Article
To read or download full-length articles you need a subscription to Ultrapure. Please log in or subscribe below.